Evidence map›Paper›PMID 31527718›Full record

ArticleScientific reports2019

Clearance of hepatitis C virus is associated with early and potent but narrowly-directed, Envelope-specific antibodies.

Melanie R Walker, Preston Leung, Auda A Eltahla, Alexander Underwood, Arunasingam Abayasingam, Nicholas A Brasher, Hui Li, Bing-Ru Wu, Lisa Maher, Fabio Luciani and 2 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Antibody Responses in Hepatitis C Infection.Cold Spring Harbor perspectives in medicine · 2021
    Review
  13. Review
  14. Article
  15. Article
  16. HCV Glycoprotein Structure and Implications for B-Cell Vaccine Development.International journal of molecular sciences · 2020
    Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Melanie R WalkerViral Immunology Systems Program, The Kirby Institute, Sydney, Australia.
Preston LeungViral Immunology Systems Program, The Kirby Institute, Sydney, Australia.ORCID http://orcid.org/0000-0002-2849-9216
Auda A EltahlaViral Immunology Systems Program, The Kirby Institute, Sydney, Australia.ORCID http://orcid.org/0000-0002-2995-8832
Alexander UnderwoodViral Immunology Systems Program, The Kirby Institute, Sydney, Australia.
Arunasingam AbayasingamViral Immunology Systems Program, The Kirby Institute, Sydney, Australia.
Nicholas A BrasherViral Immunology Systems Program, The Kirby Institute, Sydney, Australia.ORCID http://orcid.org/0000-0002-7951-8763
Hui LiViral Immunology Systems Program, The Kirby Institute, Sydney, Australia.
Bing-Ru WuViral Immunology Systems Program, The Kirby Institute, Sydney, Australia.
Lisa MaherViral Immunology Systems Program, The Kirby Institute, Sydney, Australia.
Fabio LucianiViral Immunology Systems Program, The Kirby Institute, Sydney, Australia.
Andrew R LloydViral Immunology Systems Program, The Kirby Institute, Sydney, Australia.ORCID http://orcid.org/0000-0001-6277-8887
Rowena A BullViral Immunology Systems Program, The Kirby Institute, Sydney, Australia. r.bull@unsw.edu.au.
UNSW Sydney · AUAustralian Human Rights Commission · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis C virus (HCV) is one of very few viruses that are either naturally cleared, or alternatively persist to cause chronic disease. Viral diversity and escape, as well as host adaptive immune factors, are believed to control the outcome. To date, there is limited understanding of the critical, early host-pathogen interactions. The asymptomatic nature of early HCV infection generally prevents identification of the transmitted/founder (T/F) virus, and thus the study of host responses directed against the autologous T/F strain. In this study, 14 rare subjects identified from very early in infection (4-45 days) with varied disease outcomes (n = 7 clearers) were examined in regard to the timing, breadth, and magnitude of the neutralizing antibody (nAb) response, as well as evolution of the T/F strain. Clearance was associated with earlier onset and more potent nAb responses appearing at a mean of 71 days post-infection (DPI), but these responses were narrowly directed against the autologous T/F virus or closely related variants. In contrast, a delayed onset of nAbs (mean 425 DPI) was observed in chronic progressors that appear to have targeted longitudinal variants rather than the T/F strain. The nAb responses in the chronic progressors mapped to known CD81 binding epitopes, and were associated with rapid emergence of new viral variants with reduced CD81 binding. We propose that the prolonged period of viremia in the absence of nAbs in these subjects was associated with an increase in viral diversity, affording the virus greater options to escape nAb pressure once it emerged. These findings indicate that timing of the nAb response is essential for clearance. Further investigation of the specificities of the early nAbs and the factors regulating early induction of protective nAbs is needed.

Indexed as

AdultAntibodies, NeutralizingAntibody FormationEpitopesFemaleHepacivirusHepatitis C AntibodiesHepatitis C, ChronicHost-Pathogen InteractionsHumansLongitudinal StudiesMaleTetraspanin 28Viral Envelope ProteinsViremiaYoung AdultAntibodies, NeutralizingCD81 protein, humanE1 protein, Hepatitis C virusEpitopesglycoprotein E2, Hepatitis C virusHepatitis C AntibodiesTetraspanin 28Viral Envelope Proteins

Identifiers

PMID31527718
PMCPMC6746763
OpenAlexW2974730792

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.